- GBI & PARTNERS
- I-Mab and Junshi join forces on CD73/PD-1 combo development
I-Mab and Junshi join forces on CD73/PD-1 combo development
China-based biotechs I-Mab Biopharma (Shanghai) Co., Ltd, and Shanghai Junshi biosciences Co., Ltd, have agreed to work together on a clinical study for I-Mab’s CD73 antibody TJD5 and Junshi’s programmed death-1 (PD-1) inhibitor toripalimab as a combination therapy in China. The pairing is expected to produce synergistic effects that boost the efficacy of tumor immunotherapy.
TJD5 is an in-house developed CD73 antibody that is the subject of ongoing Phase I clinical trials in the US in advanced solid tumor patients. Meanwhile, toripalimab is the subject of 30 ongoing studies across 14 different cancer indications, and was the first domestic PD-1 mAb to be approved in China at the end of 2018. Previous studies have shown that CD73 blockade in combination with PD-1 or CTLA-4 antibodies can enhance the therapeutic effect of checkpoint inhibitors and produce synergistic effects.